Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Markus Boehm, Matthew Crawford, Jamie E. Moscovitz & Philip A. Carpino. (2018) Diabetes area patent participation analysis – part II: years 2011-2016. Expert Opinion on Therapeutic Patents 28:2, pages 111-122.
Read now
Read now
Cristina M. Alcántara & Andrés R. Alcántara. (2018) Biocatalyzed synthesis of antidiabetic drugs: A review. Biocatalysis and Biotransformation 36:1, pages 12-46.
Read now
Read now
A. Brett Hauber, Hiep Nguyen, Joshua Posner, Iftekhar Kalsekar & James Ruggles. (2016) A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Current Medical Research and Opinion 32:2, pages 251-262.
Read now
Read now
Agostino Consoli & Gloria Formoso. (2015) Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opinion on Drug Safety 14:2, pages 207-218.
Read now
Read now
Irl B. Hirsch, Doron Schneider, Aaron King, William H. Polonsky, Timothy S. Reid, Jay Shubrook, Carol A. Verderese, Jeffrey Wallace & Matthew C. Riddle. (2014) A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin?—Moving Toward Personalized Management of Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 135-144.
Read now
Read now
Laura Cascales. (2012) New treatments for type 2 diabetes. Medical Writing 21:4, pages 279-283.
Read now
Read now
Articles from other publishers (49)
Heejun Park, Eun‐Sol Ha, Jeong‐Soo Kim & Min‐Soo Kim. (2023) Injectable sustained‐release poly(lactic‐co‐glycolic acid) (PLGA) microspheres of exenatide prepared by supercritical fluid extraction of emulsion process based on a design of experiment approach. Bioengineering & Translational Medicine 8:3.
Crossref
Crossref
Doanna Png, Ester Yeoh, Clara Tan & Su Chi Lim. (2023) A Pair of Siblings With Wolfram Syndrome: A Review of the Literature and Treatment Options. Journal of Investigative Medicine High Impact Case Reports 11, pages 232470962211506.
Crossref
Crossref
Xiaoyu Chen, Hongyuan Zhao, Yajun Lu, Huawei Liu, Fanqiang Meng, Zhaoxin Lu & Yingjian Lu. (2022) Surfactin Mitigates a High-Fat Diet and Streptozotocin-Induced Type 2 Diabetes through Improving Pancreatic Dysfunction and Inhibiting Inflammatory Response. International Journal of Molecular Sciences 23:19, pages 11086.
Crossref
Crossref
Ruinan Wu, Zhanghan Wu, Liyun Xing, Xi Liu, Lei Wu, Zhou Zhou, Lian Li & Yuan Huang. (2022) Mimicking natural cholesterol assimilation to elevate the oral delivery of liraglutide for type II diabetes therapy. Asian Journal of Pharmaceutical Sciences 17:5, pages 653-665.
Crossref
Crossref
. (2022)
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:
Standards of Medical Care in Diabetes—2022
. Diabetes Care 45:Supplement_1, pages S60-S82.
Crossref
Crossref
Miyuki Kobara, Hiroe Toba & Tetsuo Nakata. (2022) A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxia–Reoxygenation Injury in Cultured Cardiomyocytes. Journal of Cardiovascular Pharmacology 79:4, pages 568-576.
Crossref
Crossref
Heejun Park, Eun-Sol Ha & Min-Soo Kim. (2021) Complexation of exenatide and cyclodextrin: An approach for the stabilization and sustained release of exenatide in PLGA microsphere. Carbohydrate Polymers 266, pages 118169.
Crossref
Crossref
. (2021)
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:
Standards of Medical Care in Diabetes—2021
. Diabetes Care 44:Supplement_1, pages S53-S72.
Crossref
Crossref
Ratnakar Mishra, Benson S. Chen, Prachi Richa & Patrick Yu-Wai-Man. (2021) Wolfram syndrome: new pathophysiological insights and therapeutic strategies. Therapeutic Advances in Rare Disease 2, pages 263300402110395.
Crossref
Crossref
Dharmendra Kumar Khatri, Amey Kadbhane, Monica Patel, Shweta Nene, Srividya Atmakuri, Saurabh Srivastava & Shashi Bala Singh. (2021) Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders. Current Research in Pharmacology and Drug Discovery 2, pages 100022.
Crossref
Crossref
. (2020)
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:
Standards of Medical Care in Diabetes—2020
. Diabetes Care 43:Supplement_1, pages S48-S65.
Crossref
Crossref
Heejun Park, Dong-Hyun Ha, Eun-Sol Ha, Jeong-Soo Kim, Min-Soo Kim & Sung-Joo Hwang. (2019) Effect of Stabilizers on Encapsulation Efficiency and Release Behavior of Exenatide-Loaded PLGA Microsphere Prepared by the W/O/W Solvent Evaporation Method. Pharmaceutics 11:12, pages 627.
Crossref
Crossref
Jasmine D. Gonzalvo, Jay Hamm, Shannon Eaves, Cynthia E. Muñoz, Mary De Groot, Felicia Hill-Briggs, Marjorie Cypress & Randi Streisand. (2019) A Practical Approach to Mental Health for the Diabetes Educator. AADE in Practice 7:2, pages 29-44.
Crossref
Crossref
. (2019)
4. Comprehensive Medical Evaluation and Assessment of Comorbidities:
Standards of Medical Care in Diabetes—2019
. Diabetes Care 42:Supplement_1, pages S34-S45.
Crossref
Crossref
. (2018)
3. Comprehensive Medical Evaluation and Assessment of Comorbidities:
Standards of Medical Care in Diabetes—2018
. Diabetes Care 41:Supplement_1, pages S28-S37.
Crossref
Crossref
Guanglei Chang, Jian Liu, Shu Qin, Youqin Jiang, Peng Zhang, Hui Yu, Kai Lu, Nan Zhang, Li Cao, Ying Wang, Yong Li & Dongying Zhang. (2017) Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor/cAMP/PKA pathway. International Journal of Molecular Medicine.
Crossref
Crossref
Wen-Chun Yu, Yen-Lin Chen, Pai-An Hwang, Tso-Hsiao Chen & Tz-Chong Chou. (2017) Fucoidan ameliorates pancreatic β-cell death and impaired insulin synthesis in streptozotocin-treated β cells and mice via a Sirt-1-dependent manner. Molecular Nutrition & Food Research 61:10, pages 1700136.
Crossref
Crossref
David A. Price, Alan M. Mathiowetz & Spiros Liras. 2017. Practical Medicinal Chemistry with Macrocycles. Practical Medicinal Chemistry with Macrocycles
59
76
.
Willem van den Brink, Annette Emerenciana, Francesco Bellanti, Oscar Della Pasqua & Jan Willem van der Laan. (2017) Prediction of thyroid C-cell carcinogenicity after chronic administration of GLP1-R agonists in rodents. Toxicology and Applied Pharmacology 320, pages 51-59.
Crossref
Crossref
Lei Qin, Stephanie Chen, Emuella Flood, Alka Shaunik, Beverly Romero, Marie de la Cruz, Cynthia Alvarez & Susan Grandy. (2017) Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study. Diabetes Therapy 8:2, pages 321-334.
Crossref
Crossref
. (2017) 3. Comprehensive Medical Evaluation and Assessment of Comorbidities. Diabetes Care 40:Supplement_1, pages S25-S32.
Crossref
Crossref
Olga Montvida, Kerenaftali Klein, Sudhesh Kumar, Kamlesh Khunti & Sanjoy K. Paul. (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes, Obesity and Metabolism 19:1, pages 108-117.
Crossref
Crossref
Deborah Young-Hyman, Mary de Groot, Felicia Hill-Briggs, Jeffrey S. Gonzalez, Korey Hood & Mark Peyrot. (2016) Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 39:12, pages 2126-2140.
Crossref
Crossref
Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng & Ming-Wei Wang. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews 68:4, pages 954-1013.
Crossref
Crossref
Nan Lu, Hanxiao Sun, JingJia Yu, Xiaojing Wang, Dongmei Liu, Lin Zhao, Lihao Sun, Hongyan Zhao, Bei Tao & Jianmin Liu. (2015) Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes.. PLOS ONE 10:7, pages e0132744.
Crossref
Crossref
Yukiko Onishi, Elisabeth Niemoeller, Yukio Ikeda, Hiroki Takagi, Daisuke Yabe & Yutaka Seino. (2014)
Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of
G
et
G
oal‐
S
. Journal of Diabetes Investigation 6:2, pages 201-209.
Crossref
Crossref
Denis Raccah, Patrick Miossec, Virginie Esposito, Elisabeth Niemoeller, Meehyung Cho & John Gerich. (2014) Efficacy and safety of lixisenatide in elderly ( ≥65 years old) and very elderly ( ≥75 years old) patients with type 2 diabetes: an analysis from the GetGoal phase III programme. Diabetes/Metabolism Research and Reviews 31:2, pages 204-211.
Crossref
Crossref
Sanjoy K Paul, Kerenaftali Klein, David Maggs & Jennie H Best. (2015) The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovascular Diabetology 14:1, pages 10.
Crossref
Crossref
RM Røge, S Klim, SH Ingwersen, MC Kjellsson & NR Kristensen. (2014) The Effects of a GLP‐1 Analog on Glucose Homeostasis in Type 2 Diabetes Mellitus Quantified by an Integrated Glucose Insulin Model. CPT: Pharmacometrics & Systems Pharmacology 4:1, pages 28-36.
Crossref
Crossref
Kim V. Andreassen, Michael Feigh, Sara T. Hjuler, Sofie Gydesen, Jan Erik Henriksen, Henning Beck-Nielsen, Claus Christiansen, Morten A. Karsdal & Kim Henriksen. (2014) A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats. American Journal of Physiology-Endocrinology and Metabolism 307:1, pages E24-E33.
Crossref
Crossref
Adriana Migliorini, Erik Bader & Heiko Lickert. (2014) Islet cell plasticity and regeneration. Molecular Metabolism 3:3, pages 268-274.
Crossref
Crossref
Alessandro Pocai. (2014) Action and therapeutic potential of oxyntomodulin. Molecular Metabolism 3:3, pages 241-251.
Crossref
Crossref
Guanglei Chang, Dongying Zhang, Jian Liu, Peng Zhang, Lin Ye, Kai Lu, Qin Duan, Aihua Zheng & Shu Qin. (2014) Exenatide protects against hypoxia/reoxygenation-induced apoptosis by improving mitochondrial function in H9c2 cells. Experimental Biology and Medicine 239:4, pages 414-422.
Crossref
Crossref
Mervat E. Mohamed. (2014) Can Sitaglipten Attenuate Hypertension, Myocardial Changes and Vascular Reactivity Induced by Long Term Blockade of Nitric Oxide Synthesis in the Rat?. Open Journal of Endocrine and Metabolic Diseases 04:07, pages 197-210.
Crossref
Crossref
Yasuo Terauchi, Yoichi Satoi, Masakazu Takeuchi & Takeshi Imaoka. (2014) Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocrine Journal 61:10, pages 949-959.
Crossref
Crossref
Hitomi ODA, Akihiro MORI, Peter LEE, Kaori SAEKI, Toshiro ARAI & Toshinori SAKO. (2014) Preliminary Study Characterizing the Use of Sitagliptin for Glycemic Control in Healthy Beagle Dogs with Normal Gluco-Homeostasis. Journal of Veterinary Medical Science 76:10, pages 1383-1387.
Crossref
Crossref
Armin Bauer & Mark Brönstrup. (2014) Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep. 31:1, pages 35-60.
Crossref
Crossref
Harriet A Watkins, Dan L Rathbone, James Barwell, Debbie L Hay & David R Poyner. (2013) Structure-activity relationships for ?-calcitonin gene-related peptide. British Journal of Pharmacology 170:7, pages 1308-1322.
Crossref
Crossref
GUANGLEI CHANG, DONGYING ZHANG, HUI YU, PENG ZHANG, YING WANG, AIHUA ZHENG & SHU QIN. (2013) Cardioprotective effects of exenatide against oxidative stress-induced injury. International Journal of Molecular Medicine 32:5, pages 1011-1020.
Crossref
Crossref
Elisabetta Bianchi, Paul E. Carrington, Paolo Ingallinella, Marco Finotto, Alessia Santoprete, Aleksandr Petrov, George Eiermann, Jennifer Kosinski, Donald J. Marsh, Alessandro Pocai, Ranabir SinhaRoy & Antonello Pessi. (2013) A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity. Bioorganic & Medicinal Chemistry 21:22, pages 7064-7073.
Crossref
Crossref
Elizabeth V. DentonCody J. CraigRebecca L. PongratzJacob S. AppelbaumAmy E. DoernerArjun NarayananGerald I. ShulmanGary W. ClineAlanna Schepartz. (2013) A β-Peptide Agonist of the GLP-1 Receptor, a Class B GPCR. Organic Letters 15:20, pages 5318-5321.
Crossref
Crossref
H. Oda, A. Mori, P. Lee, K. Saeki, K. Ishioka, T. Arai & T. Sako. (2013) Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs. Research in Veterinary Science 95:2, pages 381-388.
Crossref
Crossref
Guanglei Chang, Peng Zhang, Lin Ye, Kai Lu, Ying Wang, Qin Duan, Aihua Zheng, Shu Qin & Dongying Zhang. (2013) Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model. European Journal of Pharmacology 718:1-3, pages 105-113.
Crossref
Crossref
Laurence J. Miller. (2013) Molecular basis of peptide activation of the GLP-1 receptor. Molecular Metabolism 2:2, pages 60-61.
Crossref
Crossref
Thomas J. Rosol. (2013) On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice. Toxicologic Pathology 41:2, pages 303-309.
Crossref
Crossref
Lyn H. Jones & David A. Price. 2013.
45
96
.
Michael Lehrke & Nikolaus Marx. (2012) New antidiabetic therapies. Current Opinion in Lipidology 23:6, pages 569-575.
Crossref
Crossref
Henrik K. Salling, Klaus D. D?hler, Thomas Engstr?m & Marek Treiman. (2012) Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemia-reperfusion injury in an isolated rat heart. Regulatory Peptides 178:1-3, pages 51-55.
Crossref
Crossref
M.S. Fineman, B.B. Cirincione, D. Maggs & M. Diamant. (2012) GLP‐1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism 14:8, pages 675-688.
Crossref
Crossref